SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3461Seriously, I don't think anyone made the connection between ADXS and GNCA unDewDiligence_on_SI-9/26/2017
3460Genocea (GNCA) off 70% as company drops lead program in genital herpes, cuts wortuck-9/26/2017
3459PTCT has had a good recovery since that last flop, as Ataluren managed approval tuck-9/26/2017
3458Axovant (AXON) off 74% after huge run up into late stage Alzheimer's Diseasetuck-9/26/2017
3457vktx up 15%, so we've now got two fireworks on the sales thread. ;-) I havscaram(o)uche-9/22/2017
3456That ICPT trade was a short term holding only. I even forgot that I had held itBiotech Jim-9/22/2017
3455You can count me as one of the ICPT skeptics wrt NASH.DewDiligence_on_SI-9/21/2017
3454Intercept (ICPT) off 16% as Leerink analyst suggests it's lead NASH drug coutuck-9/21/2017
3453Bavarian Nordic 50%.... COPENHAGEN, Denmark, September 14, 2017 - Bavarian Nordnigel bates-9/15/2017
3452Cellectis 30% on clinical hold.nigel bates-9/5/2017
3451Going through 10-K for first time. Looks like Chris M. got HC Ventures to convescaram(o)uche-7/28/2017
3450EGRX yesterday FDA rejects Eagle Pharmaceuticals' heat stroke treatmenttnsaf-7/27/2017
3449Thanks. In vetting XENE for my charity portfolio, I didn't scrutinize the etuck-7/5/2017
3448And another one to keep on your WL is XOMA, Which had a good performance from 4,Jibacoa-7/5/2017
3447Epilepsy program IND has slipped many times. Latest is IND this half. Won't rkrw-7/5/2017
3446And it seems that it will find support at the previously mentioned recent doubleJibacoa-7/5/2017
3445As you probably know, I have been now retired for 17 years, and have not been pJibacoa-7/4/2017
3444<After a huge run into the high $20s, CARA reports somewhat mixed P2 oral OA Miljenko Zuanic16/29/2017
3443After a huge run into the high $20s, CARA reports somewhat mixed P2 oral OA resutuck-6/29/2017
3442Annnnd XENE fails in pain, too, off 18% to multi-year lows. FWIW, the CEO once tuck-6/27/2017
3441Trying a bad news trade on NLNK. Average cost $7.25. Cheers, Tucktuck-6/8/2017
3440NewLink (NLNK) off 28% on return of its IDO inhibitor partnered with Genentech. tuck-6/8/2017
3439Thanks, noticed that, but forgot to mention it as an additional negative. Alwaysscaram(o)uche-5/18/2017
3438LPTX. Looks like cash only into about October at their current burn rate. rkrw-5/18/2017
3437Double ASCO whammy, LPTX.... microcap, ASCO abstract shows significant toxicitscaram(o)uche-5/18/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News